(Q45412595)

English

Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women

scientific article published on 9 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Matthew L Sherman

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Niels G Borgstein

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Louisa Mook

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Dawn Wilson

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Yijun Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Nianhang Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Ravindra Kumar

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Kenneth Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Abderrahmane Laadem

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

9 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1121-1130

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

The silent risks of blood transfusion

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Anemia management in oncology and hematology

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Erythropoietins: a common mechanism of action

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Erythropoietin couples hematopoiesis with bone formation

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

New agents that stimulate erythropoiesis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

The transforming growth factor-beta superfamily of receptors

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Smad transcription factors

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis).

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Activin receptor signaling: a potential therapeutic target for osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Iron Loading and Overloading due to Ineffective Erythropoiesis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

The myelodysplastic syndromes: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Beta A versus beta B: is it merely a matter of expression?

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Betaglycan binds inhibin and can mediate functional antagonism of activin signalling

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Pituitary actions of ligands of the TGF-beta family: activins and inhibins

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Importance of FSH-releasing protein and inhibin in erythrodifferentiation

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

The role of activin a in regulation of hemopoiesis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.160

21 January 2018

Identifiers

10.1002/JCPH.160

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45412595&oldid=2143960283"